All patients
Age < 65y (younger) Age > 65y ECOG 0 ECOG 1 PD-L1 < 1% PD-L1 > 1% RAS mutant RAS wild type
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
colorectal cancer (CRC), atezolizumab plus cometinib vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMblaze-370 (AC ; all population), 2019 1.00 [0.73; 1.37]
1.00 [0.73 ; 1.37 ] IMblaze-370 (AC ; all population), 2019 1 0% 273 NA not evaluable progression or deaths (PFS)detailed results IMblaze-370 (AC ; all population), 2019 1.25 [0.94; 1.66]
1.25 [0.94 ; 1.66 ] IMblaze-370 (AC ; all population), 2019 1 0% 273 NA not evaluable objective responses (ORR)detailed results IMblaze-370 (AC ; all population), 2019 1.24 [0.24; 6.50]
1.24 [0.24 ; 6.50 ] IMblaze-370 (AC ; all population), 2019 1 0% 273 NA not evaluable AE (any grade)detailed results IMblaze-370 (AC ; all population), 2019 1.52 [0.42; 5.53]
1.52 [0.42 ; 5.53 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 1.15 [0.67; 1.97]
1.15 [0.67 ; 1.97 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable AE leading to death (grade 5)detailed results IMblaze-370 (AC ; all population), 2019 1.12 [0.21; 5.90]
1.12 [0.21 ; 5.90 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results IMblaze-370 (AC ; all population), 2019 2.72 [1.15; 6.39]
2.72 [1.15 ; 6.39 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable SAE (any grade)detailed results IMblaze-370 (AC ; all population), 2019 2.26 [1.24; 4.14]
2.26 [1.24 ; 4.14 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable STRAE (any grade)detailed results IMblaze-370 (AC ; all population), 2019 2.73 [1.26; 5.89]
2.73 [1.26 ; 5.89 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable TRAE (any grade)detailed results IMblaze-370 (AC ; all population), 2019 0.74 [0.19; 2.79]
0.74 [0.19 ; 2.79 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable TRAE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.85 [0.50; 1.44]
0.85 [0.50 ; 1.44 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable TRAE leading to death (grade 5)detailed results IMblaze-370 (AC ; all population), 2019 0.89 [0.08; 9.99]
0.89 [0.08 ; 9.99 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.89 [0.08; 9.99]
0.89 [0.08 ; 9.99 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 1.81 [0.20; 16.42]
1.81 [0.20 ; 16.42 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65]
0.45 [0.01 ; 22.65 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Abdominal pain AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.29 [0.05; 1.77]
0.29 [0.05 ; 1.77 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Acute kidney injury AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65]
0.45 [0.01 ; 22.65 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Anaemia AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 2.31 [0.49; 10.78]
2.31 [0.49 ; 10.78 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Arthralgia AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.22 [0.01; 6.66]
0.22 [0.01 ; 6.66 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Asthenia AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 3.22 [0.39; 26.58]
3.22 [0.39 ; 26.58 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Back pain AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65]
0.45 [0.01 ; 22.65 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Colitis AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29]
1.80 [0.08 ; 40.29 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Constipation AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90]
0.89 [0.03 ; 26.90 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Cough AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65]
0.45 [0.01 ; 22.65 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Decreased appetite AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.44 [0.06; 3.19]
0.44 [0.06 ; 3.19 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Dermatitis acneiform AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29]
1.80 [0.08 ; 40.29 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Diarrhoea AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 1.89 [0.68; 5.22]
1.89 [0.68 ; 5.22 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Dysgeusia AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90]
0.89 [0.03 ; 26.90 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Dysphonia AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65]
0.45 [0.01 ; 22.65 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Fatigue AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.49 [0.17; 1.40]
0.49 [0.17 ; 1.40 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Guillain-Barré syndrome AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90]
0.89 [0.03 ; 26.90 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Headache AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90]
0.89 [0.03 ; 26.90 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Hypertension AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.08 [0.02; 0.37]
0.08 [0.02 ; 0.37 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Increased ALT AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.22 [0.01; 6.66]
0.22 [0.01 ; 6.66 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Infusion-related reaction AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29]
1.80 [0.08 ; 40.29 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Intestinal perforation AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.22 [0.01; 6.66]
0.22 [0.01 ; 6.66 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Mucosal inflammation AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29]
1.80 [0.08 ; 40.29 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Myalgia AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.22 [0.01; 6.66]
0.22 [0.01 ; 6.66 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Nausea AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29]
1.80 [0.08 ; 40.29 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.02 [0.00; 0.39]
0.02 [0.00 ; 0.39 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.22 [0.01; 6.66]
0.22 [0.01 ; 6.66 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 1.80 [0.08; 40.29]
1.80 [0.08 ; 40.29 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Pneumonitis AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90]
0.89 [0.03 ; 26.90 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Pruritus AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65]
0.45 [0.01 ; 22.65 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Pyrexia AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 6.47 [0.36; 115.44]
6.47 [0.36 ; 115.44 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Rash AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 1.59 [0.32; 7.82]
1.59 [0.32 ; 7.82 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Rash maculopapular AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.44 [0.03; 7.19]
0.44 [0.03 ; 7.19 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Sepsis AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.44 [0.06; 3.19]
0.44 [0.06 ; 3.19 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Stomatitis AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65]
0.45 [0.01 ; 22.65 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90]
0.89 [0.03 ; 26.90 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Vomiting AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.89 [0.03; 26.90]
0.89 [0.03 ; 26.90 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable Weight decreased AE (grade 3-4)detailed results IMblaze-370 (AC ; all population), 2019 0.45 [0.01; 22.65]
0.45 [0.01 ; 22.65 ] IMblaze-370 (AC ; all population), 2019 1 0% 259 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-30 17:45 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 126,385,183,384,137,138
- treatments: 696